Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are other bidders in the wings? OCAT now has massive success in the science and an offer on the table with the market willing to pay more than the offered price.
Did Astellas reserve the right to "increase-the-Offer" to buy OCAT?
Is Astellas part of the Mitsubishi Financial Group? If so, is mitsubishi bigger than GE...GEHC or Regeneron? If GE brings good things to life $30.00 plus dividend, then what does Regeneron bring to life?
An honest OCAT opinion from Stemdynasty.
"They've set up themselves for overwhelming failure if they don't raise the offer immediately. NO WAY POSSIBLE anyone will tender when they could sell for more than 8.50 all day long and have the cash in their account the second they sell with no stress or anxiety. So far Astellas only has a whopping 1.7% of the votes in their favor since they promised management a happy ending for only them, but management's % of ownership is irrelevant. It's very evident that the other part of the equation people would have thought would be tendering, the institutions, well they are actually BUYING SHARES ABOVE 8.50, so no way they are helping Astellas by tendering for 8.50 while they are accumulating....makes no sense.
Bottom line is when you use a little common sense we will see a higher offer BEFORE the deadline of the Dec 17th, because this tender offer is going nowhere fast, and time is on our side and against Astellas. Another offer from a competitor could most definitely be coming at anytime now that the low ball offer has set the bar so low for the entire company. I think Jeffries is whispering to their better clients this tender offer is not even in the ball park, and o one is tendering when Astellas has to compete with demand for shares on the open market willing to pay above the tender offer. So, even if shares are being sold, they are also being bought NOT TENDERED. This is Astellas worst case scenario, because this could now slip away from them for not coming in strong. Now it's either a hedgefund considering taking this private, or a competitor buying shares at these low prices to accumulate a large block of shares making it impossible for Astellas to EVER get 50.1% of the shares tendered, and they will come in with a better offer and already own a large percentage of shares making the deal easily happen.
Astellas doesn't have time on their side. Shareholders do. I anticipate a higher offer very soon as Astellas admits they could never attain the needed 50.1%. They never had to deal with shareholders that held back on putting a roof on their home, a fancier car, a vacation, even prolonged retirement to invest in this company, because they were so passionate and sure this technology would change all of medicine. Do they really think we would take a loss after close to a decade of waiting for something that is a mere 6 months from the biggest inflection point not only for this company, but for patients, regenerative medicine and all of medicine? They have no idea the resolve Ocata's shareholders have when it comes to this stock. They are beginning to realize they are going into dead end. I don't think they will risk this escalating into a bidding war and they will raise the offer BEFORE the 17th, or they risk this slipping right out of their hands. The CEO of Astellas has been vocal that he is confident this will benefit patients. He runs a 30 billion dollar company, and he know Ocata is the premiere cell therapy on the planet, so he would never let this slip thru his fingers for a few extra dollars which in the scheme of things will pay for itself countless times over. JMHO Good luck LONGS."
Is the OCAT market price above or below the offer?
A wonderful day to all that are capable of appreciating life.
https://www.youtube.com/user/PositiveMagazine
In other words like they said in the old days, "hang loose, mongoose"
Attack on blind teen in Huntington Beach, but bully was stopped by observer. Goes to show that OCATs needed benefits have huge merit in restoration of sight.
Linda Ronstadt knows about STEM CELLS merit.
Perhaps a "worry free island" ahead. Interesting OCAT post:
This came in from Stemdynasty.
"Normally, I would agree with your statement that a competitive offer has time, but not in this case. As a matter of fact, the longer this drags, the better FOR SHAREHOLDERS. I continue to point out that we will see the photoreceptor paper this quarter, the updates on clinicaltrials.gov, and potentially injections and SPA. The longer Astellas wants to drag this out, the more a competitor is accumulating millions of shares, and the more likely we will get a positive pr to prove management is working for its shareholders if for some reason this falls apart. They have no assurances, none, so management has to perform their duties. A new bidder can come in and look at what this management accomplished, and see they were sitting on their hands and immediately fire them all. No job, no future job, no million dollar payoffs if they show they are not in this to advance the science. It would be immoral, and unethical not to continue to perform at 100%, and as we know this will all be shown in court if this gets to that point. I wouldn't want to be in front of a judge or jury and have to explain they intentionally stalled progress while they had a fiduciary responsibility to continue to work for their shareholders.
Right now, we the shareholders are driving the bus. Not management. Remember that. We don't agree with the offer price. That's where we stand. Others had an opportunity to hear Eddy at the AAO. I think it overwhelmingly made the case that this IS AND WILL BE A CURATIVE THERAPY. A cure is a huge threat to everyone sitting in that room listening unless you are a surgeon. Then you are giddy with anticipation. Regeneron IMO will come in with an offer, and I think they are sneaky enough to be buying shares right now. They didn't get to be the 800lb gorilla by sitting on their LAURELS. I take that back, this time they will be sitting directly on Laurel, hehe."
Thanks for the info Lasers.
"IMO the Shorts are not covering and purchasing of shares is by a Retail or Institution @$8.50 that believes $OCAT PPS is going higher."
For those that do not know what OCAT has accomplished.
http://ois.net/ocata-therapeutics-2015/
Being a patient advocate is of true value for sure.
It has been said the good things happen to those that wait.
OCAT trading above the offer price is interesting.
Every once in a while a interesting OCAT post comes in.
"Higher offer vs Astellas walking away
I would consider this reassuring a higher offer is likely if no one tenders
"We highly value Ocata's R&D capabilities, including its world-leading researchers in cell therapy," Yoshihiko Hatanaka, president and chief executive officer of Astellas, said in a statement. "We're confident that we will turn innovative science into value for patients through the creation of new value by combining both companies' capabilities under 'One Astellas,' where Ocata will be taking a key role in Astellas' R&D in ophthalmology and cell therapy."
The CEO of Astellas sounds very motivated to buy, not walk away. He noted 2 things succinctly: Ocata's world-leading researchers will be his, and he uses the word CONFIDENT this works and will benefit patients (now bare in mind that they had full access to ALL OF THE DATA not just 22 they reported---actually all of the pipeline as well). He is anxious to own this company and has visions of glory becoming a hero to his country.
For less than the jv (680MM) between Avalanche and Regeneron, and not even remotely in the ball park of the Cephalon/ Mesoblast deal for 2 Billion they will own AMD, SMD, and MMD, and all of the other beyond proof of concept therapies in the pipeline which included, Crohn's, ms, lupus, uveitis, blood and platelets. Think just about their prize position heading back to Japan....MMD. They will literally have the know how, the top scientists in the world, and all the IP which is patented in Japan
Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year.
In addition they have this which WE, THE SHAREHOLDERS PAID FOR: The deal will also affect other business partners of Ocata’s, such as Allele Biotech, whose mRNA technology Ocata licenses to produce iPSC lines for treating diseases of the eye. Allele’s “footprint-free” reprogramming technology gave Ocata a consistent and scalable process for producing iPSCs that could be “used to manufacture millions of treatment doses as off-the-shelf therapies,” according to the Ocata announcement about the deal in March 2015.
They also capitalize on this as well: it has reported positive results for a number studies, most recently announcing that Asian patients with macular degeneration treated with Ocata’s proprietary RPE cells experienced positive results.
Add this: Another recent success for Ocata was the finding that dogs treated with its proprietary hemangio-derived mesenchymal cell (HMCTM) technology achieved remission of anal furunculosis (CAF), a condition exhibiting similar traits to Crohn’s disease.
Astellas plans to use the acquisition to further strengthen its ophthalmology products and establish itself in the area of cell therapy, a diversification beyond traditional drug-based approaches.
Top blogger and world renowned cell biologist, Dr Paul Knoepfler's comments: "My initial reaction is that this isn’t reflective of the full value of Ocata".
I believe now the author of the Seeking Alpha report that said the stock was going to zero WILL HAVE TO BE INVESTIGATED BECAUSE THIS IS A HUGE REASON THE OFFER PRICE WAS NOT REFLECTIVE OF OCATA'S FULL VALUE.
This is key and why this has to be investigated because it harmed shareholders and the date is very suspect.
NOTE: On Sept 23, 2015, the SA report which said Ocata is valued at zero was published.
NOTE: On September 24 and 25, 2015, Astellas, Ocata and their respective representatives met at the Boston office of Goodwin Procter LLP (“Goodwin”), Ocata’s outside legal counsel, to conduct in-person due diligence meetings, and certain representatives of Astellas also visited Ocata’s facilities in Marlborough, Massachusetts. The meetings also included presentations given by Ocata regarding its research and development program, clinical development, human resources, legal and financial matters, as well as regulatory compliance matters.
The bid was based on the share price NOT THE MARKET CAP. Had it not been based on the share price (which was severely deflated over a planned, coordinated short attack the day before Ocata was meeting Astella's executives to give a presentation and re-evaluate their offer) it would have been 400MM, 500MM, or some round number, but not a round number for the share price like 8.50 ....I am again using common sense here explaining that we were undervalued because of this PERFECTLY TIMED, VERY DAMAGING, HIGHLY COORDINATED SHORT ATTACK. Lawyers are going to have a field day with this finding I have shared with shareholders.
More to come to justify a higher price is deserved and IMO coming."
Last edited by stemdynasty; Today at 11:31 PM.
Can you degrade the benefits and value of improving human eyesight in public without an agenda? The value of OCAT went up to $27.00 with success in rats and now with humans the value is much higher. IMO humans have more value than rats except those that devalue helping the afflicted.
If Japan ends up being the rich guys with the cigars who would appreciate that? Not to be funny but you get my drift. A partnership with Japan is more plausible. They need the science as well as other countries. IMO The three OCAT entities that are worthy of support are as follows. The patients, the science and the shareholders. You choose the correct order.
In fact truth is sometimes stranger than fiction. If one was going to mock the science of a company that has helped improve patients eyes and recorded in a peer reviewed scientific journal they must have a strange reason to not value such success.
And through it all here are a few quotes:
1)"These past 2 weeks of 21M share accumulation in this company is very interesting indeed."
2)"My fiduciary at Fidelity said a lot of times things are intentionally announced on the weekend, so traders can't react, so he and I will be watching. He laughed as he said who is buying up all these shares at par and above the offering price, because that's a lot of risk with no upside, so he says it's a very positive sign. He can't recall a time when the share price consistently traded above average volume at or above the offering without a leak or some reassurance the bid is going to be raised. I trust his judgment, because he has 30 years in the markets and one of the top strategists for fidelity. He's a fiduciary, not an investment advisor. He has a moral and ethical obligation to have my back"
3)"However the offer is below at least one analyst’s target price of $9.00 per share.
Return on Investment for Ocata Therapeutics, Inc. (NASDAQ:OCAT) is 1300.00% and on Monday its shares closed at $8.46. Ocata Therapeutics" ........this last one number 3 came from Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City
Good for you, thanks for showing us your success. Wishing the best for OCAT as well.
OCAT went green and is worth more than the big Japan-Pharma offer with plenty of upside in perceived value. The cost of putting together the historic game changing quality peer reviewed "in pocket" OCAT data recognized by Silicon Valley Bank confirms OCATs perceived value as OCATs recognition and awareness grows.
OCAT post quote: "Very interesting. Going after the individual schemers and not the company."
Several Key Elements are developing.
OCAT stimulus can now be understood by market with OCAT,s scalable manufacturing process. Years ago they could not comprehend but now:
"OCAT has the peer reviewed data. Ocata is now on the front page and it makes people understand that the deal OCATA has with Silicon Valley Bank shows new value as SVB also invest in GEHC "General Electric Health Care". Momentum builds with Japans interest. Feeding fenzey comes to mind which equates to higher value. Latest NIH grants to OCATA show pharma they can work with company."
Lowering the cost of health care "end result".
OCAT can bring the cost of health care down. "Bottom-line"
I'm glad OCATA has 38 million in the bank and Silicon Valley Bank in it's corner. More banks feel more comfortable now with OCAT becoming more desireable to pharma and the market understands upside.
Several Key Elements are developing.
I'd like to add this to this list.
OCAT stimulus can now be understood by market with OCAT,s scalable manufacturing process.
"OCAT has the peer reviewed data. Ocata is now on the front page and it makes people understand that the deal OCATA has with Silicon Valley Bank shows new value as SVB also invest in GEHC. Momentum builds with Japans interest. Feeding fenzey comes to mind which equates to higher value. Latest NIH grants to OCATA show pharma they can work with company."
OCAT has the peer reviewed data. Ocata is now on the front page and it makes people understand that the deal OCATA has with Silicon Valley Bank shows new value as SVB also invest in GEHC. Momentum builds with Japans interest. Feeding fenzey comes to mind which equates to higher value. Latest NIH grants to OCATA show pharma they can work with company.
OCAT has a fist full of patents and a fist full of dollars. Facts mam.
Imagine how big the OCAT blood patents are something to think about.
Stronger than a butterfly.
Search these key words. "ocat blood patent"
Stanford stem cell product, delayed for more than a decade, to be ...
www.mercurynews.com/ california/ ci_28308095/ stan... Proxy Highlight
Jun 14, 2015 ... His goal is to use them to regenerate patients' blood-forming systems after .... Weissman's hands at Stanford -- although Novartis still holds the patent. ... Also, OCAT's stem technology covers production of platelets, blood cells,
Also: "Company Name: Ocata Therapeutics Inc., Stock Symbol: OCAT, Industry: ... we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other .."
"Also, OCAT's stem technology covers productions of platelets, blood cells..."
After hours OCAT's up, higher competitive bidders may want to partner instead of buyout. With Japan's Astellas taking action, it gives OCATA opportunity with "higher-bids" in the wings possible. Most deals happen when both parties are some what happy.
In the event that Japan's Astelas wants to sweeten and make a better deal for both parties, it still has to ward off higher bidders in the event they come in.
Post in from Anise:
"I have every reason to be HAPPY to see this technology going to Japan, I need the cure more than any amount of profit, and I STILL would not tender shares for $8.50. If possible, it's even less likely that I would flat out sell them now. That makes no sense at all to me. So if I wouldn't do it, and if anybody would be doing it, that someone should be me... then I think that everyone needs to make up their own minds about people who are so eager to tell us what a good idea it is."
Interesting OCAT post: Perhaps a Linear Correlation
"Assuming that it can't be Astellas or one of their affiliated entities, I am also starting to think those 16.8M shares that traded since last Tuesday, are – apart from some short covering – weak (or uneducated) hands selling into stronger hands, who are speculating that a higher offer is likely. Why sink in millions of dollars for a modest $0.05 gain? Probably not. If the above thesis proves right, maybe the higher the volume so far, the better chances are that the tender will initially fail. We're trading very close to the offer price."
"Just for reference, I was watching in my broker account another tender offer, FedEx offering to pay € 8.00 for each TNT share (closing by January 8th 2016 it seems). On Euronext Amsterdam, primary market for this stock, TNTE.AS closed at € 7.68 today, roughly 4% under the offered price. The equivalent discount for Ocata would result in $8.16. Obviously, it looks like $OCAT is "more popular" among buyers, as the discount is just 0.5%. I hope that suggests, people with deep pockets are scooping up these shares in order to say "no" to the tender at $8.50. The reverse strategy (saying "yes"), would signify an awfully large investment for a ridiculously small gain. Does that make sense?"
I agree north40000. That guy could make it more easy on himself and keep it simple. There are many potential white knights in rusty armor and a few without rust.
The patients that need the benefits of OCAT science get theirs when the powers that be get their act together.
By packman:
OCAT perspective post:
I INVESTED $50,000 additional at $8.47 PPS. Why? $8.50 is the base. We will leverage the offer by Astellas. The Big Pharma holding the NDAs now need to pay for the price to bid. If this was a true auction where they can take 20 to 30% commission, this is a bargain when the POTENTIAL value of the science and more importantly the array of patents are worth upward of multiple Billions.
I don't see this selling to any Japanese company. If there is an Asian white knight, it would be Cha. If there is a European white knight, there are possible suitors. As much as I want this medical breakthrough to stay in the USA, antiquated FDA and NIH will surely guarantee that millions will go blind from a curative treatment.
I would only prefer shares from a powerhouse big pharma outside the USA. How close is the FDA process? One prime example is Ofirmev. It was readily available in Europe for YEARS, yet the FDA wanted additional safety protocols. It is simply an IV form of Tylenol.
At this point, I am averaging UP. Although I started my position at 0.21 (pre split), I invested heavily in the sub 3s and sub 4s. I even chased it up from the low 4s.
I believe in the All or None phenomenon. I am ALL in. Waiting on the mystery river card.
It should be obvious that I have not sold any shares and will vote NO to my sizable LONG position.
http://www.williamshaker.com/why-discomfort-is-good-for-you-how-to-become-mentally-strong/
New Morningstar Q3 OCAT-reports. thanks to Iamaverb
Northern Trust increased their holdings 492%
Oppenhiemer increased their holdings 380%
Goldman increased their holdings 343%
BNY Mellon increased their holdings 120%
Vanguard 98%
Bridgeway 48%
Appraise this: "Potential to block all current competitors" @pfizer $OCAT @OcataThx iCell - http://investorstemcell.com/forum/ocata-ma
John Redaelli
?@twenty2John
Appraise this: "Potential to block all current competitors" @pfizer $OCAT @OcataThx iCell - http://investorstemcell.com/forum/ocata-main-forum-general-topics-science-prs-media-etc/52467-5.htm#post327723 …
Embedded image permalink
"Court decisions regarding "Fair Value" Post from Manowar:
I thought this pertinent to the discussion, this is a recent Delaware court case ruling on two cases regarding fair value and arbitrage dealings from hedge funds.
http://r.search.yahoo.com/_ylt=A0LEV...bxvlGaJAwXAGc-
Worth reading and checking on some more of this type!
Another pertinent topic!
DELAWARE INSIDER: When Business Judgement Isn?t Enough: The Impact of the Standard of Review on Deal Litigation | Business Law Section
http://www.americanbar.org/publications/blt/2014/05/delaware_insider.html
Another pertinent case study!
Mergers & Acquisitions | Paul, Weiss
http://www.paulweiss.com/practices/transactional/mergers-acquisitions/publications/delaware-court-of-chancery-relies-exclusively-on-merger-price-less-net-synergies-to-determine-fair-value-in-appraisal-action.aspx?id=20192
Marlborough Regional Chamber of Commerce
You are here: Home / Contact Us
Contact Us
Email Us
Call Us: 508-485-7746
"Just as a reminder, Ocata has been granted the Advanced Therapy Medicinal Product or ATMP designation for its RPE therapy for macular degeneration in Europe. This designation is an essential step in allowing companies to commercialize products effectively across the European Union."
"bidding wars" sometimes happen
OCAT Quote post: "He missed the most important quote that from the CFO and COO ted miles, he's the number two person in the company and he said something to the effect I'm not here for six dollars a share I'm here for 20, 30or $40 a share. We need to send to the author this audio so he can post the audio people can hear Ted's voice and exact words in that article in my opinion"
OCAT POST: ... "So What Happens if Gary-Aronson puts Forth a Counter Offer?"
"I for one am cheering Gary Aronson on as I would like nothing more than to see Gary Aronson organize a true counter offer. Could you imagine if he can rally some big boys and come to the table with a $500-$1B counter offer and ultimately takeover Ocata?
Shareholders and all the funds and institutions IMO would jump at this counter and if he can get close to $750M or more then IMO Astelles will say uncle.
Then I hope the new owners will immediately terminate PW, TM, EA and LJ employment along with the entire BOD's include Heffernan with the exception of Dr. Langer. Nothing would please me more, as what comes around goes around. IMO get them all out ASAP!
I'd be very happy to see Gary Aronson step in as the new CEO of the company and bring in an entire new team but would ask that his first hire be Matt Vincent while also elevating Dr. Lanza as a member of the BOD's.
This would keep the science in American hands and put a stop to all the craziness shareholders have experienced these past 18 months under the current leadership. Lanza and his team could rest easy that they will continue to be the ultimate drivers of the science and not having to always be overlooking their shoulder.
At that point with the thousands of loyal retail investors walking away with a nice profit my bet is many, many of us would reinvest some of our profits and buy some of the remaining 17M shares in a private offering of the 60M A/S even at $20 pps as a show of support to Dr. Lanza to help ensure he and his scientific team can get this science through phase 2 trials when a real inflection point will occur.
By the end of 2017 IMO BP will not be able to ignore Ocata and Gary with Dr. Lanza's guidance will be able to hand pick who they feel is the best future match for Ocata.
Also I would advise GA to role out a new employee incentive plan where 70% of these shares MUST be awarded to the Ocata "worker bees" as a commitment and thank you to them for their incredible service.
Surely Gary Aronson has already thought this through as IMO he would like nothing better than to own Ocata and allow Dr. Lanza the full opportunity to change the world forever!"
This post written by: BF ... Bogeyfree